

DEC 30 2002

JAN 02 2003

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/007,555	TECH CENTER 1600/2900	DOCKET NO.: B00801.70233.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: October 25, 2001	CONFIRMATION NO.: 5204	
		APPLICANT: Colgan et al.		
		GROUP ART UNIT: 1614	EXAMINER: unknown	
Sheet 1 of 1				

## U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

## FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
my	B1	WO	96/39426	A1	PCT	12-12-1996	
	B2	WO	98/14615	A1	PCT	04-09-1998	
	B3	WO	99/09046	A1	PCT	02-25-1999	
	B4	WO	00/69908	A1	PCT	11-23-2000	
↓	B5	WO	02/02609	A1	PCT	01-10-2002	

## OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
my	C1	CANIGGIA et al., "Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGF $\beta$ 3." <i>J. of Clinical Investigation</i> , Vol.105, No. 5, March 2000, pp.577-587.	
	C2	COMERFORD et al., "Hypoxia-inducible Factor-1-dependent Regulation of the Multidrug Resistance (MDR1) Gene" <i>Cancer Research</i> , 62, pp.3387-3394, June 15, 2002.	
	C3	SEMENTZA et al., "Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression." <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 35(2): 71-103 (2000).	
	C4	SEMENTZA et al., "Hypoxia-inducible factor 1: master regulator of O <sub>2</sub> homeostasis." <i>Current Opinion in Genetics &amp; Development</i> , vol. 8, no. 5, October 1998, pp.588-594.	
	C5	WALLACE et al. "Induction of multidrug resistance (mdr-1) gene by hypoxia." <i>Molecular Biology of the Cell</i> , Vol. 11, no. Supplement, December 2000, p. 435a. (abstract)	
↓	C6	Communication Relating to the Results of the Partial International Search, PCT/US01/49856, November 18, 2002	

EXAMINER	DATE CONSIDERED
<i>Mike Y</i>	2-11-05

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application. Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

FEB 06 2003

FEB 03 2003

FORM PTO-1449/A and B (Modified)

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 1

TEST CENTER 1600/2900 APPLICATION NO. 007,255		ATTY. DOCKET NO.: B00801.70233.US
FILING DATE: October 25, 2001		CONFIRMATION NO.: 5204
APPLICANT: Colgan et al.		
GROUP ART UNIT: 1614		EXAMINER: unknown

## U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
my	A1	5,882,914	A	Semenza	03-16-1999
↓	A2	6,001,991	A	Dean, et al.	12-14-1999
↓	A3	6,020,462	A	Semenza	02-01-2000

## FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

## OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
my	C7	BROWN, JM "Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies." <i>Molecular Medicine Today</i> . 6:157-162 (April 2000).	
	C8	FARDEL, O., et al. "The P-glycoprotein multidrug transporter." <i>Gen Pharmacol.</i> , 27(8):1283-91 (1996)	
	C9	JIN, S., et al. "Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y." <i>Molecular and Cellular Biology</i> 18:4377-4384 (1998).	
	C10	KAYE, SB. "Multidrug resistance: clinical relevance in solid tumors and strategies for circumvention." <i>Curr Opin Oncol.</i> 10(suppl. 1):S15-S19. (1998)	
	C11	LIANG, BC., "Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines." <i>J Neuro-Oncology</i> . 29:149-155 (1996).	
	C12	RYAN, HE., et al. "HIF-1 $\alpha$ is required for solid tumor formation and embryonic vascularization." <i>EMBO Journal</i> . 17(11):3005-3015 (1998).	
	C13	SEmenza, GL., et al. "Regulation of mammalian O <sub>2</sub> homeostasis by hypoxia-inducible factor 1." <i>Annu. Rev. Cell Dev Biol.</i> 15:551-78 (1999)	
	C14	STRAUSS, BE et al. "The region 3' to the major transcriptional start site of the mdrl downstream promoter mediates activation by a subset of mutant P53 proteins." <i>Biochem Biophys Res Commun.</i> 217(1):333-340 (1995).	
	C15	SUTHERLAND, RM "Tumor hypoxia and gene expression - implications of malignant progression and therapy." <i>Acta Oncol.</i> 37(6):567-74. (1998).	
	C16	UEDA, K "Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine." <i>Proc. Natl. Acad. Sci. USA</i> 84:3004-3008 (1987).	
	C17	UEDA, K., et al. "Isolation and sequence of the promoter region of the human multidrug resistance (P-glycoprotein) gene." <i>J. Biol. Chem.</i> 262(36):17432-17436 (1987).	
	C18	UEDA, K., et al. "The human multidrug resistance (mdrl) gene." <i>J. Biol. Chem.</i> 262(2):505-508 (1987)	
↓	C19	UEDA, K., et al. "The mdrl gene, responsible for multidrug-resistance codes for p-glycoprotein." <i>Biochem Biophys Res Commun.</i> 141(3):956-962. (1986).	

EXAMINER

*Misra*

DATE CONSIDERED

*2-11-05*

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

MAR 20 2003

FORM PTO-1449/A and B (Modified)

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Sheet 1 of 1

APPLICATION NO.: 10/007,255	ATTY DOCKET N# B0080170233-18
FILING DATE: October 25, 2001	CONFIRMATION NO. 5204
APPLICANT: Colgan et al.	
GROUP ART UNIT: 1614	EXAMINER: unknown

## U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of Issue of Cited Document
		Number	Kind Code		
					MAR 24 2003
					TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
my	B6	WO	98/20038		The Univ. of Texas, Board of Res.	05-14-1998	
✓	B7	WO	00/36148		Isis Pharmaceuticals, Inc.	06-23-2000	

## OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
my	C7	KRETZ-REMY et al., "SUMO/sentrin: protein modifiers regulating important cellular functions," <i>Biochem Cell Biol.</i> , 77: 299-309 (1999).	
✓	C8	MAO et al., "SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage," <i>PNAS</i> , 97, No. 8: 4046-4051 (2000).	
✓	C9	International Search Report for PCT/US01/49856; Date of Search: February 6, 2003 (Mailed February 17, 2003).	

EXAMINER

*Misra J*

DATE CONSIDERED

2-11-05

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application. Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications)

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]